IP Library Granted Patent US 10,975,428
Granted Patent B2
US 10,975,428 · App. 16/081,894 · Granted Apr 13, 2021

Mutant pore

Inventors: Lakmal Jayasinghe (Oxford, GB); Elizabeth Jayne Wallace (Oxford, GB)
Assignee: Oxford Nanopore Technologies Ltd.
C12Q1/6869C07K14/245G01N33/48721C12Q2565/631
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,975,428
App. No.
16/081,894
Granted
Apr 13, 2021
Kind
B2
Abstract

The invention relates to mutant forms of CsgG. The invention also relates to analyte detection and characterisation using CsgG.

Claims (9)

1. A method for determining the presence, absence, or one or more characteristics of a target analyte, comprising:

(a) contacting the target analyte with a pore such that the target analyte moves with respect to the pore, wherein the pore is a homo-oligomer that comprises a mutant CsgG monomer comprising a variant of the sequence shown in SEQ ID NO: 2 which comprises: R97W; R93W; R93Y and R97Y; F191T; deletion of V105, A106 and I107; and/or deletion of one or more of positions R192, F193, I194, D195, Y196, Q197, R198, L199, L200 and E201; and

(b) taking one or more measurements as the analyte moves with respect to the pore and thereby determining the presence, absence or one or more characteristics of the analyte.

2. The method of claim 1 , wherein the variant comprises R97W.

3. The method of claim 1 , wherein the variant comprises deletion of F193, I194, D195, Y196, Q197, R198 and L199 or deletion of D195, Y196, Q197, R198 and L199.

4. The method of claim 1 , wherein the variant comprises one or more of the following: (i) one or more mutations at the following positions N40, D43, E44, S54, S57, Q62, R97, E101, E124, E131, R142, T150 and R192; (ii) mutations at Y51/N55, Y51/F56, N55/F56 or Y51/N55/F56; (iii) Q42R or Q42K; (iv) K49R or K94Q; (v) N102R, N102F, N102Y or N102W; (vi) D149N, D149Q or D149R; (vii) E185N, E185Q or E185R; (viii) D195N, D195Q or D195R; (ix) E201N, E201Q or E201R; (x) E203N, E203Q or E203R; (xi) deletion of one or more of the following positions F48, K49, P50, Y51, P52, A53, S54, N55, F56 and S57; and (xii) one or more mutations at the following positions L90, N91, I95, A99, Q114.

5. The method of claim 1 , wherein the variant comprises (a) a mutation at Y51 and/or F56, and/or (b) a mutation at R192, and/or (c) a mutation at T150.

6. The method of claim 5 , wherein the mutation at Y51 is Y51A, and/or the mutation at F56 is F56Q, and/or the mutation at R192 is R192D.

7. The method of claim 1 , wherein the pore comprises nine identical mutant CsgG monomers.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2019
From: JAYASINGHE, LAKMAL; WALLACE, ELIZABETH JAYNE
To: OXFORD NANOPORE TECHNOLOGIES LTD.
Reel/Frame 048479/0478 →
Priority Claims (3)
GB 1603656 · Mar 2, 2016 · national
GB 1603657 · Mar 2, 2016 · national
GB 1603658 · Mar 2, 2016 · national
Continuity (1)
Related Publication 20190071721A1 · Mar 7, 2019
Cited By (9)
US 12,227,800 US 12,258,375 US 12,275,761 US 12,371,458 US 12,493,024 US 12,644,879 US 12,662,703 US 12,679,872 US 12,686,886